Patents by Inventor Maria S. Kahn

Maria S. Kahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumor immunotherapy using anti-idiotypic antibodies
    Patent number: 5614610
    Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor.
    Type: Grant
    Filed: July 28, 1988
    Date of Patent: March 25, 1997
    Assignee: Oncogen
    Inventors: Ingegerd Hellstrom, Karl E. Hellstrom, Maria S. Kahn, Donna F. Beaton
  • Biosynthesis of 2 keto-L-gulonic acid
    Patent number: 5082785
    Abstract: A process of producing 2-keto-L-gulonic acid from sorbose via a recombinant bacteria including expression vectors and probes for producing said recombinant bacteria.
    Type: Grant
    Filed: January 30, 1987
    Date of Patent: January 21, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ronald F. Manning, Maria S. Kahn
  • Tumor immunotherapy using anti-idiotypic antibodies
    Patent number: 4918164
    Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor.
    Type: Grant
    Filed: November 4, 1987
    Date of Patent: April 17, 1990
    Assignee: Oncogen
    Inventors: Ingegerd Hellstrom, Karl E. Hellstrom, Maria S. Kahn
  • Biosynthesis of 2 keto-L-gulonic acid
    Patent number: RE34851
    Abstract: A process of producing 2-keto-L-gulonic acid from sorbose via a recombinant bacteria including expression vectors and probes for producing said recombinant bacteria.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: February 7, 1995
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ronald F. Manning, Maria S. Kahn